Publicaciones científicas

/cun/investigacion/publicaciones-cientificas/areaMain/02
  • The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Martínez-Vélez N (1,2,3), Garcia-Moure M (1,2,3), Marigil M (1,2,3), González-Huarriz M (1,2,3), Puigdelloses M (1,2,4), Gallego Pérez-Larraya J (1,2,4), Zalacaín M (1,2,3), Marrodán L (1,2,3), Varela-Guruceaga M (1,2,3), Laspidea V (1,2,3), Aristu JJ (1,5), Ramos LI (1,5), Tejada-Solís S (1,6), Díez-Valle R (1,6), Jones C (7,8), Mackay A (7,8), Martínez-Climent JA (1,9), García-Barchino MJ (1,9), Raabe E (10,11), Monje M (12), Becher OJ (13), Junier MP (14), El-Habr EA (14), Chneiweiss H (14), Aldave G (15), Jiang H (16), Fueyo J (16,17), Patiño-García A (1,2,3), Gomez-Manzano C (18), Alonso MM (19,20,21).

    (1) Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (2) Program of Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Navarra, Pamplona, Spain.
    (3) Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (6) Department of Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain.
    (7) Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, Surrey, SM2 5NG, UK.
    (8) Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, Surrey, SM2 5NG, UK.
    (9) Division of Hematopoietic Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, CIBERONC, Pamplona, Pamplona, Navarra, Spain.
    (10) Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    (11) Division of Pediatric Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    (12) Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA.
    (13) Department of Pediatrics, Northwestern University and Division of Pediatric Hematology-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA.
    (14) CNRS UMR8246, Inserm U1130, Neuroscience Paris Seine - IBPS, Sorbonne Universities, Paris, France.
    (15) Division of Pediatric Neurosurgery, Department of Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
    (16) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (17) Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (18) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (19) Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (20) Program of Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Navarra, Pamplona, Spain.
    (21) Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.

    Nature Communications 28 de MAYO de 2019

  • The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma

    Aldave G (1), Gonzalez-Huarriz M (2,3,4), Rubio A (5), Romero JP (5), Ravi D (5), Miñana B (6), Cuadrado-Tejedor M (3,7,8), García-Osta A (3,7), Verhaak R (9, 10), Xipell E (2,3,4), Martinez-Vélez N (2,3,4), Acanda de la Rocha A (2,3,4), Puigdelloses M (2,3,4), García-Moure M (2,3,4), Marigil M (2,3,4), Gállego Pérez-Larraya J (2,3,4), Marín-Bejar O (3,11), Huarte M (3,11), Carro MS (12), Ferrarese R (12), Belda-Iniesta C (13), Ayuso A (13,14), Prat-Acín R (15), Pastor F (3,16), Díez-Valle R (3,4,17), Tejada S (3,4,17), Alonso MM (2,3,4).

    (1) Division of Pediatric Neurosurgery, Department of Surgery, Texas Children´s Hospital, Department of Neurosurgery, Baylor College of Medicine. Houston, Texas, USA.
    (2) Department of Pediatrics, University Hospital of Navarra, Pamplona, Navarra, Spain.
    (3) The Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (4) Program in Solid Tumors, Foundation for the Applied Medical Research, Pamplona, Navarra, Spain.
    (5) CEIT and TECNUN, University of Navarra, San Sebastian, Spain.
    (6) Centre de Regulació Genòmica (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain, Universitat Pompeu-Fabra, Barcelona, Spain.
    (7) Neurobiology of Alzheimer´s Disease, Neurosciences Division, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain.
    (8) Anatomy Department, School of Medicine, University of Navarra, Pamplona, Spain.
    (9) Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
    (10) Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
    (11) Department of Gene Therapy and Regulation of Gene Expression, Center for Applied Medical Research, CIMA, University of Navarra, Pamplona, Spain.
    (12) Department of Neurosurgery (Neurocenter) Universitätsklinikum Freiburg, Freiburg, Germany.
    (13) Fundación de Investigación HM Hospitales, Grupo HM, Spain.
    (14) Facultad de Medicina, Universidad CEU-San Pablo, Madrid, Spain.
    (15) Department of Neurosurgery, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
    (16) Program of Molecular Therapies, Aptamer Unit, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.
    (17) Department of Neurosurgery, University Hospital of Navarra, Pamplona, Navarra, Spain.

    Neuro Oncology 24 de ENERO de 2018

  • Emerging clinical issues and multivariate analyses in PET investigations

    Arbizu J (1), Giuliani A (2), Perez-Larraya JG (3), Riverol M (3), Jonsson C (4), García-García B (5), Morales M (5), Imaz L (3), Pagani M (6,7). (1) Department of Nuclear Medicine, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain
    (2) Environment and Health Department, Istituto Superiore di Sanità, Rome, Italy.
    (3) Department of Neurology, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (4) Medical Radiation Physics and Nuclear Medicine, Imaging and Physiology, Karolinska University Hospital, Stockholm, Sweden.
    (5) Department of Nuclear Medicine, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (6) Institute of Cognitive Sciences and Technologies, CNR, Rome, Italy.
    (7) Department of Nuclear Medicine, Karolinska Hospital Stockholm, Stockholm, Sweden.

    The quarterly journal of nuclear medicine and molecular imaging 27 de JULIO de 2017

  • A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

    Inogés S (1,2), Tejada S (3), de Cerio AL (4,5), Pérez-Larraya JG (6), Espinós J (7), Idoate MA (8), Domínguez PD (9), de Eulate RG (9), Aristu J (10), Bendandi M (11,12), Pastor F (13), Alonso M (14), Andreu E (5), Cardoso FP (4,15), Valle RD (16). (1) Cell Therapy Area, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (2) Immunology and Immunotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (3) Neurosurgery Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (4) Cell Therapy Area, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (5) Immunology and Immunotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (6) Neurology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (7) Oncology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (8) Pathology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (9) Radiology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (10) Radiation Oncology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (11) Section on Hematology/Oncology, Department of Internal Medicine, Comprehensive Cancer Center, Wake Forest University Baptist Healthcare Center, Winston-Salem, NC, USA.
    (12) Section of Hematology/Oncology, Department of Internal Medicine, W.G Hefner VA Medical Center, Salisbury/Charlotte, NC, USA.
    (13) Program of Molecular Therapies, Aptamer Unit, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Avenida Pio XII 55, 31008, Pamplona, Navarra, Spain.
    (14) Program in Solid Tumors and Biomarkers, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Avenida Pio XII 55, 31008, Pamplona, Navarra, Spain.
    (15) Haematology and Haemotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (16) Neurosurgery Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain

    Journal of Transational Medicine 12 de MAYO de 2017

  • Descripción de una serie de pacientes con diagnóstico de enfermedad priónica

    Ortega-Cubero S (1), Pagola I (2), Luquin MR (2), Viteri C (2), Pastor P (3), Gállego Pérez-Larraya J (2), de Castro P (2), Domínguez I (4), Irimia P (2), Martínez-Vila E (2), Arbizu J (5), Riverol M (2).
    (1) Departamento de Neurología, Clínica Universidad de Navarra, Pamplona, Navarra, España; Laboratorio de Neurogenética, Neurociencias, Centro de Investigación Médica Aplicada, Universidad de Navarra, Pamplona, Navarra, España.
    (2) Departamento de Neurología, Clínica Universidad de Navarra, Pamplona, Navarra, España.
    (3) Departamento de Neurología, Clínica Universidad de Navarra, Pamplona, Navarra, España; Laboratorio de Neurogenética, Neurociencias, Centro de Investigación Médica Aplicada, Universidad de Navarra, Pamplona, Navarra, España.
    (4) Laboratorio de Neurogenética, Neurociencias, Centro de Investigación Médica Aplicada, Universidad de Navarra, Pamplona, Navarra, España.
    (5) Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Pamplona, Navarra, España.

    Neurología 01 de ABRIL de 2015

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra